Login to Your Account



NDA IN FIRST HALF OF 2015

Nicox shares climb as lead drug Vesneo hits mark in pivotal glaucoma trials

By Cormac Sheridan
Staff Writer

Thursday, September 25, 2014
Shares in Nicox SA climbed more than 20 percent Thursday on news that its lead drug candidate, Vesneo (latanoprostene bunod), which is partnered with Bausch + Lomb, hit the primary endpoint in two phase III pivotal trials in glaucoma, paving the way for a new drug application during the first half of 2015.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription